Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
AstraZeneca and Merck & Co.
Description:
Lung cancer is the worldwide leading cause of cancer-related
mortality. The vast majority of these cases (about 85%) are
characterized as non-small cell lung cancer (NSCLC). In recent
years, NSCLC has been found to have a multidimensional typology and
etiology driven by molecular changes in lung tissue. The knowledge
that the molecular structure of tumor cells has been altered has led
to the development of novel checkpoint inhibitors (ICI). It was only
recently that ICIs have approved for treating patients with stage
III disease following concurrent chemoradiation therapy, the aim of
which is to prevent disease progression.
Upon completion of this
activity, participants will be able to:
-
Identify key economic challenges
surrounding management of patients with early stage NSCLC,
including stage III disease
-
Discuss the managed care
considerations of current and emerging immunotherapies by
exploring where these agents fit into the current stage III and
earlier NSCLC management paradigm
-
Analyze strategies used by managed
care organizations to facilitate high quality care for members
with stage III and earlier NSCLC, and how recent immunotherapy
approvals will affect those strategies
-
Apply methods to enable optimal cost
management of immunotherapies to be realized by multiple stage
III and earlier NSCLC stakeholders including managed care
organizations
-
Explain the role of the managed care
professional in optimizing the use of checkpoint inhibitor
therapy for unresectable stage III NSCLC and opportunities to
advance managed care services
Faculty: |
Gary Owens, MD
President
Gary Owens Associates |
Disclosure:
|
Dr. Owens
serves as a consultant for Eli Lilly and Roche. His
presentation has been peer reviewed for any bias. |
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Will Williams has no relevant financial relationships to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 creditsTM.
The American Association of Managed Care Nurses (AAMCN) is
accredited as a provider of nursing continuing professional
development by the American Nurses Credentialing Center’s Commission
on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hour toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
AstraZeneca and Merck & Co.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |